Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: A 24-week randomized, double-blind exploratory study

Neuropsychiatric Disease and Treatment

Volumn 6, Issue 1, 2010, Pages 71-79

  Olié, Jean Pierre ^a   Gourion, David ^b   Montagne, Agnès ^c   Rostin, Michel ^c   Poirier, Marie France ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b Pierre Fabre Médicament ^*  (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Adult; Major depressive episode; Milnacipran; Serotonin and norepinephrine reuptake inhibitors; Venlafaxine

Indexed keywords

MILNACIPRAN; VENLAFAXINE;

ADULT; AGED; AGITATION; ANEURYSM RUPTURE; ANXIETY; ARTICLE; BILIARY COLIC; BLOOD PRESSURE; BRUXISM; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DECOMPRESSION; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; EVENING DOSAGE; FEMALE; HEART PALPITATION; HEART RATE; HUMAN; HYPERHIDROSIS; LEG FRACTURE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; ORGASM DISORDER; OUTPATIENT DEPARTMENT; RANDOMIZED CONTROLLED TRIAL; SCROTAL PAIN; SIDE EFFECT; TENSION; TREATMENT DURATION; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; UTERINE TUBE ABSCESS; VOMITING; XEROSTOMIA;

EID: 77950839217     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Weissman MM, Bland RC, Canino GJ, et al. Cross national epidemiology of major depression and bipolar disorder. JAMA. 1996;27:293-299.
2. Lépine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol. 1997;1:19-29.
3. Murray CJL, Lopez A. The Global Burden of Disease (volume I in The Global Burden of Disease and Injury Series). Harvard University Press, Boston, MA, USA; 1996.
4. Guze SB, Robins E. Suicide and primary affective disorders. Br J Psychiatry. 1970;117:437-438.
5. Le Pape A, Lecomte T. Prévalence et prise en charge médicale de la dépression, France 1996-1997. CREDES, Paris; 1999.
6. Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin. 2006;22:1825-1837.
7. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10:732-747.
8. Ansseau M, Von Frenckell R, Gérard MA, et al. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine. Eur Neuropsychopharmacol. 1991;1:113-121.
9. Hayashi M, Mimura M, Otsubo T, Kamijima K. Effect of high-dose milnacipran in patients with depression. Neuropsychiatr Dis Treat. 2007;3:699-702.
10. Okumura K, Furukawa TA. Remission rates with milnacipran 100 mg/day and 150 mg/day in the long term treatment of major depression. Clin Drug Invest. 2006;26:135-142.
11. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran treatment for fibromyalgia syndrome: one-year durability of response. Neurology. 2008;70 suppl 1:A162 (abstract).
12. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatology. 2009;36:1-12.
13. Lecrubier Y, Weiller E, Hergueta T, et al. MINI Mini International Neuropsychiatric Interview. French version 5.0.0. Hôpital de la Pitié Salpétrière, INSERM, Paris; 1998.
14. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;13:382-389.
15. Guy W. Clinical Global Impressions In: ECDEU Assessment Manual for Psychopharmacology. Publication ADM No.76-338. National Institute of Mental Health,Rockville, MD, USA; 1976.
16. Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol. 2007;22:323-329.
17. Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2009;259:172-185.
18. Kasper S. Everyday problems in treating depression: focus on SNRIs. CNS Spectr. 2008;13(7 Suppl 11):4-5.
19. Steen A, Den Boer JA. A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder. Int Clin Psychopharmacol. 1997;12(5):269-281.
20. Deakin JFW. Does selectivity matter? Int Clin Psychopharmacol. 1996;11 Suppl 1:13-17.
21. Möller HJ, Volz HP. Drug treatment of depression in the 1990s: an overview of achievements and future possibilities. Drugs. 1996;52:625-638.
22. Olié JP, Gourion D, Montagne A, Rostin M, Poirier MF. Milnacipran et venlafaxine à posologie flexible (jusqu'à 200 mg/j) dans le traitement ambulatoire des épisodes dépressifs majeurs modérés à sévères de l'adulte: étude exploratoire de 24 semaines, randomisée en double insu. Encephale. 2009;35:595-604.